REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...
Revlimid plus rituximab is the first chemotherapy-free combination regimen approved in Europe for patients with follicular lymphoma who have relapsed or did not respond to previous treatment Approval ...
For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...
Dr. Reddy’s has obtained the Food and Drug Administration's approval for lenalidomide capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results